MAIA Biotechnology Inc.(MAIA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MAIA MAIA Biotechnology Inc.

Pre-Mkt 06-10 05:37:04 EDT

1.30

+0.03

+2.36%

盘前1.33

+0.03+2.31%

05:36 EDT

High1.33	Low1.26	Vol612.09K
Open1.29	D1 Closing1.27	Amplitude5.51%
Mkt Cap78.87M	Tradable Cap72.31M	Total Shares60.67M
T/O786.79K	T/O Rate1.10%	Tradable Shares55.62M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MAIA","market":"US","secType":"STK","nameCN":"MAIA Biotechnology Inc.","latestPrice":1.3,"timestamp":1781035200000,"preClose":1.27,"halted":0,"volume":612088,"hourTrading":{"tag":"盘前","latestPrice":1.33,"preClose":1.3,"latestTime":"05:36 EDT","volume":140,"amount":186.20000000000002,"timestamp":1781084184119,"change":0.03,"changeRate":0.023077,"amplitude":0},"delay":0,"changeRate":0.02362204724409451,"floatShares":55623100,"shares":60671491,"eps":-0.665719,"marketStatus":"Pre-Mkt","change":0.03,"latestTime":"06-10 05:37:04 EDT","open":1.29,"high":1.33,"low":1.26,"amount":786785.8111352001,"amplitude":0.055118,"askPrice":1.48,"askSize":100,"bidPrice":1.19,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-0.665719,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1781098200000},"marketStatusCode":1,"adr":0,"listingDate":1659067200000,"exchange":"AMEX","adjPreClose":1.3,"preHourTrading":{"tag":"盘前","latestPrice":1.33,"preClose":1.3,"latestTime":"05:36 EDT","volume":140,"amount":186.20000000000002,"timestamp":1781084184119,"change":0.03,"changeRate":0.023077,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":1.32,"preClose":1.3,"latestTime":"19:50 EDT","volume":9489,"amount":12456.5585,"timestamp":1781049003208,"change":0.02,"changeRate":0.015385,"amplitude":0.038},"volumeRatio":0.27726404746766764},"requestUrl":"/m/hq/s/MAIA/wiki","defaultTab":"wiki","newsList":[{"id":"2640316357","title":"MAIA Biotechnology reports 29 patients dosed in Phase 3 THIO-104 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2640316357","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640316357?lang=en_us&edition=fundamental","pubTime":"2026-06-04 21:50","pubTimestamp":1780581010,"startTime":"0","endTime":"0","summary":"MAIA Biotechnology (MAIA) provided a patient enrollment update for its ongoing pivotal Phase 3 trial, THIO-104, evaluating its novel telomere-targe...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maia-biotechnology-reports-29-patients-dosed-in-phase-3-thio-104-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maia-biotechnology-reports-29-patients-dosed-in-phase-3-thio-104-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MAIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640687421","title":"MAIA Biotech doses 29 patients in Phase 3 THIO-104 lung cancer trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2640687421","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640687421?lang=en_us&edition=fundamental","pubTime":"2026-06-04 21:45","pubTimestamp":1780580714,"startTime":"0","endTime":"0","summary":"Maia Biotechnology reported strong enrollment momentum in THIO-104, a pivotal Phase 3 trial of ateganosine in third-line advanced non-small cell lung cancer.No new efficacy results were presented; the update focused on trial progress and timing for future readouts.29 patients have been dosed across 34 active sites in six countries, with a target of up to 100 patients by year-end.An interim analysis is expected in 2027 once survival follow-up matures, setting the next key catalyst for the program.Ateganosine holds FDA Fast Track status, supporting a potentially accelerated development and regulatory path if Phase 3 data are positive.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nNDL9HYVqc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","SG9999014021.USD","SG9999014039.USD","LU0314104364.USD","BK4112","MAIA","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","BK4585","NDAQ","BK4139","IE00BGHQF748.EUR","LU2095319765.USD","IE00BKPKM429.USD","BK4588","LU2210149790.SGD","IE00BN0W2W23.USD","SG9999014013.SGD","LU2210150020.SGD","SG9999014005.SGD","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640168788","title":"Maia Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2640168788","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640168788?lang=en_us&edition=fundamental","pubTime":"2026-06-04 21:45","pubTimestamp":1780580700,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nTUA4MW6GB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MAIA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640900487","title":"MAIA Gets FDA Clearance for Enrollment in Expanded Phase 2 Cancer Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2640900487","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640900487?lang=en_us&edition=fundamental","pubTime":"2026-06-03 22:23","pubTimestamp":1780496602,"startTime":"0","endTime":"0","summary":"MAIA Biotechnology  said Wednesday it has received clearance from the US Food and Drug Administration to open enrollment for the expansion of the phase 2 THIO-101 trial of ateganosine for advanced non-small cell lung cancer.The firm said it obtained clearance of its updated investigational new drug application highlighting improved manufacturing capabilities, including new manufacturers and formulation.In addition to the US, the THIO-101 study is ongoing at 44 clinical sites in six countries, it added.The additional data from the expansion studies may further support a filing for an accelerated approval, MAIA said.Shares were up over 4% in morning trading.Price: 1.41, Change: +0.06, Percent Change: +4.44","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","MAIA","BK4139","BK4588","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640900874","title":"MAIA Biotechnology receives FDA clearance for amendment to IND application","url":"https://stock-news.laohu8.com/highlight/detail?id=2640900874","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640900874?lang=en_us&edition=fundamental","pubTime":"2026-06-03 21:55","pubTimestamp":1780494955,"startTime":"0","endTime":"0","summary":"MAIA Biotechnology (MAIA) announced that the U.S. Food and Drug Administration has cleared an amendment to update its investigational new drug appl...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maia-biotechnology-receives-fda-clearance-for-amendment-to-ind-application-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maia-biotechnology-receives-fda-clearance-for-amendment-to-ind-application-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAIA","BK4588","BK4585","BK4139","LABU","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640690716","title":"Maia Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 Thio-101 Trial Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2640690716","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640690716?lang=en_us&edition=fundamental","pubTime":"2026-06-03 21:45","pubTimestamp":1780494300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nTUA8ZYMYV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MAIA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640946299","title":"MAIA Biotechnology announces open market purchases by CEO, director","url":"https://stock-news.laohu8.com/highlight/detail?id=2640946299","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640946299?lang=en_us&edition=fundamental","pubTime":"2026-06-02 21:52","pubTimestamp":1780408340,"startTime":"0","endTime":"0","summary":"MAIA Biotechnology (MAIA) announced that its founder and CEO Vlad Vitoc, M.D. and Director Stan Smith, Ph.D. have increased their ownership positio...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maia-biotechnology-announces-open-market-purchases-by-ceo-director-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maia-biotechnology-announces-open-market-purchases-by-ceo-director-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAIA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640946283","title":"Analysts Offer Insights on Healthcare Companies: West Pharmaceutical Services (WST) and MAIA Biotechnology, Inc. (MAIA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2640946283","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640946283?lang=en_us&edition=fundamental","pubTime":"2026-06-02 21:50","pubTimestamp":1780408234,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on West Pharmaceutical Services (WST) and MAIA Biotechn...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-west-pharmaceutical-services-wst-and-maia-biotechnology-inc-maia-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-west-pharmaceutical-services-wst-and-maia-biotechnology-inc-maia-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0345774391.USD","WST","LU0345774631.USD","LU0012050646.USD","HCSG","IE00BYQQ9H92.USD","IE00B64QTZ34.USD","MAIA","BK4588","XBI","BK4137","BK4504","BK4585","LU0128526141.USD","LU0106261612.USD","IE00BFXG0V08.USD","LU0029874061.USD","LABU","BK4567","BK4139","XLV","BK4121","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640466159","title":"MAIA says directors, officers hold 20.46% beneficial stake","url":"https://stock-news.laohu8.com/highlight/detail?id=2640466159","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640466159?lang=en_us&edition=fundamental","pubTime":"2026-06-02 21:48","pubTimestamp":1780408139,"startTime":"0","endTime":"0","summary":"Maia Biotechnology disclosed open-market stock purchases by founder-CEO Vlad Vitoc and director Stan V. Smith.Vitoc bought 72,700 shares on June 6 at an average price of $1.39.Smith bought 75,000 shares on June 6 at an average price of $1.34.Directors and officers collectively hold a 20.46% stake.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maia Biotechnology Inc. published the original content used to generate this news brief on June 02, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nNDL44LYW4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MAIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640563946","title":"Maia Biotechnology Announces Open Market Purchases by CEO and Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2640563946","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640563946?lang=en_us&edition=fundamental","pubTime":"2026-06-02 21:45","pubTimestamp":1780407900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nTUA2RVKRR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MAIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640943009","title":"Maia Biotechnology CEO Vlad Vitoc buys 72,700 common shares for $100,870.29","url":"https://stock-news.laohu8.com/highlight/detail?id=2640943009","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640943009?lang=en_us&edition=fundamental","pubTime":"2026-06-02 21:02","pubTimestamp":1780405371,"startTime":"0","endTime":"0","summary":"Maia Biotechnology CEO Vlad Vitoc bought 72,700 common shares at a weighted average price of $1.39.Form 4 also reports 210,100 common shares held indirectly through his spouse.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maia Biotechnology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 02, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nNDL7j7kl5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MAIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640943026","title":"Maia Biotechnology director Stan Smith acquires 75,000 shares valued at $100,200","url":"https://stock-news.laohu8.com/highlight/detail?id=2640943026","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640943026?lang=en_us&edition=fundamental","pubTime":"2026-06-02 21:02","pubTimestamp":1780405329,"startTime":"0","endTime":"0","summary":"Maia Biotechnology director Stan V. Smith reported a purchase of 75,000 common shares at a weighted average price of USD 1.34.Beneficial ownership rose to 1,519,178 shares held indirectly.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maia Biotechnology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 02, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nNDLbVvkMq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Maia Biotechnology director Stan Smith acquires 75,000 shares valued at $100,200","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MAIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640394374","title":"Maia Bio CSO Sergei Gryaznov acquires 2,000 common shares worth $2,690","url":"https://stock-news.laohu8.com/highlight/detail?id=2640394374","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640394374?lang=en_us&edition=fundamental","pubTime":"2026-06-02 21:01","pubTimestamp":1780405295,"startTime":"0","endTime":"0","summary":"Maia Biotechnology Chief Scientific Officer Sergei Gryaznov reported a purchase of 2,000 common shares at USD 1.35 each.His directly held stake rose to 46,511 shares following the transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maia Biotechnology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 02, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nNDL7BrVC2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MAIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640592669","title":"Maia Biotech presents Phase 3 THIO-104 trial design for ateganosine in checkpoint-resistant lung cancer at ASCO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2640592669","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640592669?lang=en_us&edition=fundamental","pubTime":"2026-06-01 20:02","pubTimestamp":1780315320,"startTime":"0","endTime":"0","summary":"Maia Biotechnology presented a “trial in progress” poster at ASCO 2026 on its pivotal Phase 3 THIO-104 study design.No clinical results were reported; the poster covered methodology, with screening and enrollment underway in Europe and Asia.THIO-104 is testing ateganosine, a telomere-targeting agent, sequenced with an immune checkpoint inhibitor in third-line advanced NSCLC.The study targets patients whose disease has resisted prior checkpoint inhibitors and chemotherapy, aiming to improve outcomes versus standard chemotherapy.The first patient was dosed in December 2025, marking the start of the pivotal program’s execution phase.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDL5m5V3m:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAIA","LU0314104364.USD","LU2095319765.USD","BK4139","IE00B64PRP62.GBP","NDAQ","LU2210150020.SGD","IE00BN0W2T93.GBP","BK4588","IE00BN0W2V16.EUR","SG9999014005.SGD","BK4112","BK4585","SG9999014039.USD","IE00BGHQF748.EUR","SG9999014021.USD","IE00BN0W2W23.USD","IE00B3QW5Z07.USD","IE00BKPKM429.USD","SG9999014013.SGD","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640120959","title":"Maia Biotechnology Presents Trial in Progress Poster for Pivotal Phase 3 Clinical Trial of Novel Telomere Targeting Agent at 2026 Annual Meeting of American Society of Clinical Oncology","url":"https://stock-news.laohu8.com/highlight/detail?id=2640120959","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640120959?lang=en_us&edition=fundamental","pubTime":"2026-06-01 20:00","pubTimestamp":1780315203,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nTUA3KP9X6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MAIA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640959041","title":"MAIA Biotechnology Presents Trial in Progress Poster for Pivotal Phase 3 Clinical Trial of Novel Telomere Targeting Agent at 2026 Annual Meeting of American Society of Clinical Oncology","url":"https://stock-news.laohu8.com/highlight/detail?id=2640959041","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640959041?lang=en_us&edition=fundamental","pubTime":"2026-06-01 20:00","pubTimestamp":1780315200,"startTime":"0","endTime":"0","summary":"CHICAGO, June  01, 2026  (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunothe","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/01/3304325/0/en/MAIA-Biotechnology-Presents-Trial-in-Progress-Poster-for-Pivotal-Phase-3-Clinical-Trial-of-Novel-Telomere-Targeting-Agent-at-2026-Annual-Meeting-of-American-Society-of-Clinical-Onc.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4097","BK4139","LU0053666078.USD","BK4107","BK4588","LU0210528500.USD","CPI","PRGS","MAIA","BK4117","L","LU2487616109.SGD","AFG","LU2065732104.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637331565","title":"MAIA Biotechnology Shareholders Back Board and Auditor Appointments","url":"https://stock-news.laohu8.com/highlight/detail?id=2637331565","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637331565?lang=en_us&edition=fundamental","pubTime":"2026-05-22 18:33","pubTimestamp":1779446038,"startTime":"0","endTime":"0","summary":"MAIA Biotechnology, Inc. ( ($MAIA) ) has provided an announcement. On May 21, 2026, MAIA Biotechnology, Inc. held its 2026 Annual Meeting of stockh...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/maia-biotechnology-shareholders-back-board-and-auditor-appointments?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/maia-biotechnology-shareholders-back-board-and-auditor-appointments?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAIA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637331384","title":"Maia Biotechnology shareholders ratify Grant Thornton as 2026 auditor","url":"https://stock-news.laohu8.com/highlight/detail?id=2637331384","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637331384?lang=en_us&edition=fundamental","pubTime":"2026-05-22 18:05","pubTimestamp":1779444305,"startTime":"0","endTime":"0","summary":"Maia Biotechnology held its annual shareholder meeting on May 21, 2026.Votes also supported seating the company’s Class I director nominees for new three-year terms running to the 2029 annual meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maia Biotechnology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 22, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nNDLngxFQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MAIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635722186","title":"MAIA Biotechnology Ends ATM Stock Offering Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2635722186","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635722186?lang=en_us&edition=fundamental","pubTime":"2026-05-15 07:15","pubTimestamp":1778800521,"startTime":"0","endTime":"0","summary":"MAIA Biotechnology, Inc. ( ($MAIA) ) has issued an announcement. On May 14, 2026, MAIA Biotechnology, Inc. suspended sales of its common stock unde...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/maia-biotechnology-ends-atm-stock-offering-agreement?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/maia-biotechnology-ends-atm-stock-offering-agreement?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAIA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635999729","title":"Maia Biotechnology Inc - Sold 3.1 Mln Shares for Gross Proceeds of $5.7 Mln Under Sales Agreement - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2635999729","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635999729?lang=en_us&edition=fundamental","pubTime":"2026-05-15 05:05","pubTimestamp":1778792709,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nFWN41R1FU:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MAIA"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.MAIABiotech.com","stockEarnings":[{"period":"1week","weight":-0.037},{"period":"1month","weight":-0.0152},{"period":"3month","weight":-0.172},{"period":"6month","weight":-0.2073},{"period":"1year","weight":-0.2778},{"period":"ytd","weight":-0.1503}],"compareEarnings":[{"period":"1week","weight":-0.0296},{"period":"1month","weight":-0.0008},{"period":"3month","weight":0.0898},{"period":"6month","weight":0.0695},{"period":"1year","weight":0.2291},{"period":"ytd","weight":0.0808}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. MAIA Biotechnology, Inc. was incorporated in 2018 and is headquartered in Chicago, Illinois.","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.285723},{"month":2,"riseRate":0,"avgChangeRate":-0.06082},{"month":3,"riseRate":0.25,"avgChangeRate":-0.026788},{"month":4,"riseRate":0.5,"avgChangeRate":0.130553},{"month":5,"riseRate":0.75,"avgChangeRate":0.111873},{"month":6,"riseRate":0.25,"avgChangeRate":-0.11479},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.058081},{"month":8,"riseRate":0,"avgChangeRate":-0.148704},{"month":9,"riseRate":0.25,"avgChangeRate":0.000086},{"month":10,"riseRate":0.25,"avgChangeRate":-0.039628},{"month":11,"riseRate":0.25,"avgChangeRate":-0.189158},{"month":12,"riseRate":0.5,"avgChangeRate":0.077797}],"exchange":"AMEX","name":"MAIA Biotechnology Inc.","nameEN":"MAIA Biotechnology Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"MAIA Biotechnology Inc.(MAIA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest MAIA Biotechnology Inc.(MAIA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"MAIA Biotechnology Inc.,MAIA,MAIA Biotechnology Inc.股票,MAIA Biotechnology Inc.股票老虎,MAIA Biotechnology Inc.股票老虎国际,MAIA Biotechnology Inc.行情,MAIA Biotechnology Inc.股票行情,MAIA Biotechnology Inc.股价,MAIA Biotechnology Inc.股市,MAIA Biotechnology Inc.股票价格,MAIA Biotechnology Inc.股票交易,MAIA Biotechnology Inc.股票购买,MAIA Biotechnology Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"MAIA Biotechnology Inc.(MAIA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest MAIA Biotechnology Inc.(MAIA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}